Feminai is an Israeli health-tech startup building a wearable sensor patch that continuously monitors breast tissue density and blood-flow patterns, then analyzes the data with proprietary AI algorithms to detect early signs of breast cancer. The company’s first in-human clinical trial at Sheba Medical Center reported 96% sensitivity and a 98% negative predictive value, indicating strong diagnostic accuracy. Co-founded by physician-CEO Dr. Karny Ilan along with Gal Yanuka and Shani Klein, Feminai aims to replace or supplement clinic-based imaging with a more accessible, affordable, and user-friendly home solution. The recent seed funding equips the team to scale hiring, pursue regulatory clearances, and finalize go-to-market preparations. Feminai ultimately intends to bring its device to global markets as a subscription or device-plus-software service, targeting earlier detection and improved outcomes for women’s health. Prior to the seed round, no additional funding amounts were disclosed.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2026